Ocular Therapeutix chief strategy officer resigns to lead private company
Sanjay Nayak notified the company of his resignation effective October 16, 2026, to take the CEO role at a privately-held firm.
Ocular Therapeutix, Inc. disclosed in an 8-K filing that its Chief Strategy Officer, Sanjay Nayak, M.B.B.S., Ph.D., is leaving the company. On October 14, 2026, Nayak notified the company of his resignation, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.1
The filing, dated October 14, 2026 as the earliest event reported, was signed on October 16, 2026 by Jason S. Robins, the company's Chief Financial Officer. Robins signed the report in his capacity as Chief Financial Officer of Ocular Therapeutix, Inc.1
The disclosure was made under Item 5.02 of Form 8-K, which covers departures of directors or certain officers and related compensatory arrangements. The filing did not name the privately-held company Nayak is joining, nor did it disclose any severance or transition arrangements tied to his departure.
Ocular Therapeutix is headquartered at 14 Crosby Drive, 3rd Floor, Bedford, Massachusetts, and its common stock trades on The Nasdaq Global Market under the ticker symbol OCUL. The company is incorporated in Delaware.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.